Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients
- 17 April 2017
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 94 (2), 327-333
- https://doi.org/10.1002/cyto.b.21527
Abstract
In natalizumab-treated relapsing-remitting MS (RRMS) patients, various extended interval dosing strategies are under evaluation to minimize severe treatment-associated side effects, mainly progressive multifocal leukoencephalopathy development. Up to now, it has not been presented any approach, even in form of assay design, to determine the optimal percentage of CD49d receptor occupancy (RO) associated with a favorable clinical, radiological, and immunological response. A multiparametric quantitative flow cytometry method was settled to measure CD49d RO on peripheral blood lymphocytes. The analytical protocol was tested in a 6-month follow-up from 19 RRMS patients treated with the natalizumab standard dosing of every 4 weeks or an extended-interval dosing of every 6 weeks. Extended natalizumab dose schedule promoted an increase of CD49d molecules per cell surface and a reduction of CD49d RO levels. The reduction observed on CD49d RO was not only depending on dose schedule but also on individual parameters such as body mass. Interestingly, individual clinical outcome was apparently the same between the different dose schedules or even better with the extended interval dosing. Following up CD49d RO levels with a well-regulated monitoring work scheme is crucial to further identify over-/under-treated patients and to define a safe, personalized natalizumab regimen. © 2017 International Clinical Cytometry SocietyKeywords
Funding Information
- Instituto de Salud Carlos III
- Generalitat de Catalunya
This publication has 16 references indexed in Scilit:
- Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumabCytometry Part B: Clinical Cytometry, 2015
- Extended interval dosing of natalizumab: a two-center, 7-year experienceTherapeutic Advances in Neurological Disorders, 2014
- Inter‐laboratory assessment of flow cytometric monocyte HLA‐DR expression in clinical samplesCytometry Part B: Clinical Cytometry, 2012
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2012
- CD49d expression as a promising biomarker to monitor natalizumab efficacyJournal of the Neurological Sciences, 2012
- Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cellsJournal of Neuroimmunology, 2011
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesThe Lancet Neurology, 2010
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- Monitoring Temporary Immunodepression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multicenter Standardized StudyClinical Chemistry, 2005
- Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MSExpert Review of Neurotherapeutics, 2004